InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

FATE THERAPEUTICS INC

FATE Clue Score25
United States Fiscal year ends December CIK 0001434316 Results filed 5 Nov 2026
Add to watchlist

What the insiders did Net buying

Individual transactions

8
Insider
Date
Role
Action
Shares
Price
Amount
Redmile Group, LLC
20 Dec 2024
Director
Buy indirect
397,964
$1.68
$668.58K
Redmile Group, LLC
26 Dec 2023
Director
Buy indirect
44,630
$3.72
$166.02K
Redmile Group, LLC
21 Apr 2023
Director
Buy indirect
256,639
$6.18
$1.59M
Redmile Group, LLC
20 Apr 2023
Director
Buy indirect
20,000
$5.99
$119.80K
Redmile Group, LLC
14 Apr 2023
Director
Buy indirect
25,700
$6.00
$154.20K
John Mendlein
13 Jan 2023
Director
Buy
36,631
$5.43
$198.91K
John Mendlein
11 Jan 2023
Director
Buy
88,048
$5.67
$499.23K
Redmile Group, LLC
8 Jan 2021
Director
Buy indirect
327,485
$85.50
$28.00M
Showing 250 of 388 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 299
Amendments (4/A) skipped 6
Filings about a different issuer 0
Unreadable filings 0
Joint filings 21
Sales on a Rule 10b5-1 plan 11
Sales straight out of an exercise 155
Sales at will 198
Transactions with no price 0
Shares from compensation/vesting 38,862,198
Sales filed before the plan box existed 178
History held since 7 Oct 2013